Gensia
Executive Summary
Registers initial public offering of 2.5 mil. shares of common stock. Underwriters are Alex. Brown, Montgomery Securities and Smith Barney, Harris Upham & Co. Gensia has two adenosine regulating agents (ARAs) in Phase II trials for cardiovascular disease; the firm's lead compound is ARA-100. Earlier this year, Marion Merrell Dow made a $15 mil. equity investment in Gensia to back its ARA R&D ("The Pink Sheet" Feb. 12, T&G-5).
Registers initial public offering of 2.5 mil. shares of common
stock. Underwriters are Alex. Brown, Montgomery Securities and
Smith Barney, Harris Upham & Co. Gensia has two adenosine
regulating agents (ARAs) in Phase II trials for cardiovascular
disease; the firm's lead compound is ARA-100. Earlier this year,
Marion Merrell Dow made a $15 mil. equity investment in Gensia to
back its ARA R&D ("The Pink Sheet" Feb. 12, T&G-5). |